Harbour BioMed Expands AstraZeneca Partnership for Next-Generation Oncology Therapeutics
核心洞察
Harbour BioMed (搜索) announced an advancement of its global strategic collaboration with AstraZeneca, originally established in March 2025, to discover and develop next-generation biotherapeutics in oncology (搜索).
The expanded partnership will see AstraZeneca nominate discovery programs to Harbour BioMed (搜索) annually over the next four years, focusing on antibody-drug conjugates (搜索) and T cell engagers (搜索).
Harbour BioMed (搜索) will receive option fees, development milestones, commercial milestone payments, and tiered royalties on future net sales from licensed programs under the collaboration.
Harbour BioMed (搜索) has announced an advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology (搜索). The partnership, originally established in March 2025, will focus on developing antibody-drug conjugates (搜索) (ADCs) and T cell engagers (搜索) leveraging both companies' expertise.
Expanded Collaboration Framework
Under the updated agreement terms, AstraZeneca will continue to nominate discovery programs to Harbour BioMed (搜索) each year over the next four years, reflecting the continued progress of the partnership. AstraZeneca will retain the option to license these programs for further development, while Harbour BioMed will be eligible to receive option and option exercise fees, development and commercial milestone payments, plus tiered royalties on future net sales on licensed programs. The economic terms remain consistent with the financial framework established in March 2025.
Established Partnership Foundation
The collaboration builds on a relationship that began in 2022, with Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed (搜索), noting that "over time, the two parties have established a trusted and solid partnership." Wang emphasized that Harbour BioMed's proprietary antibody platforms position the company to "support AstraZeneca in developing innovative biotherapeutics that can address significant unmet medical needs and improve patient outcomes globally."
Proprietary Technology Platform
Harbour BioMed (搜索)'s competitive advantage lies in its proprietary antibody technology platform, Harbour Mice®, which generates fully human monoclonal antibodies (搜索) in both conventional two heavy and two light chain (H2L2) format and heavy chain-only (HCAb) format. The company has developed specialized technologies building upon HCAb antibodies, including the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology that enables tumor (搜索)-killing effects that traditional combination therapies cannot achieve.
Additionally, the HCAb-based bispecific immune cell antagonist (HBICA™) technology empowers the development of innovative biologics for immunological and inflammatory diseases (搜索). By integrating Harbour Mice®, HBICE®, and HBICA™ with a single B-cell cloning platform, Harbour BioMed (搜索) has built what the company describes as "a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies."
Strategic Positioning
Harbour BioMed (搜索) is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. The company is committed to the discovery and development of novel antibody therapeutics in immunology and oncology (搜索), positioning itself as a global biopharmaceutical company focused on addressing significant medical needs through innovative therapeutic approaches.